Proteomic applications for the early detection of cancer.
The ability of physicians to effectively treat and cure cancer is directly dependent on their ability to detect cancers at their earliest stages. Proteomic analyses of early-stage cancers have provided new insights into the changes that occur in the early phases of tumorigenesis and represent a new resource of candidate biomarkers for early-stage disease. Studies that profile proteomic patterns in body fluids also present new opportunities for the development of novel, highly sensitive diagnostic tools for the early detection of cancer.
Wulfkuhle
Julia D
JD
NCI/FDA Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.
Liotta
Lance A
LA
Petricoin
Emanuel F
EF
D014408:Biomarkers, Tumor / Q000097:blood* / Q000235:genetics; D006801:Humans; D009363:Neoplasm Proteins / Q000097:blood* / Q000235:genetics; D009369:Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000235:genetics; D020543:Proteome / Q000032:analysis*; D040901:Proteomics / Q000379:methods*
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D020543:Proteome